Nasdaq · CIK 0001075880
KZIA KAZIA THERAPEUTICS LTD
Insider trading from SEC Form 4. Last filing Jul 8, 2026.
In brief
KAZIA THERAPEUTICS LTD (KZIA) has 8 SEC Form 4 filings on file from 8 insiders, the latest filed on Jul 8, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at KAZIA THERAPEUTICS LTD, scored.
Transactions
Every row filed, 9 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Robert F Apple director | AGrant or award Employee Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jul 8, 2026 |
| Jan 8, 2026 | Jeffrey Bonacorda VP, Finance and Controller | AGrant or award Employee Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jul 8, 2026 |
| Jan 8, 2026 | David Cain Director, CMC | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jul 8, 2026 |
| Jan 8, 2026 | Steven R. S. Coffey director | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jul 8, 2026 |
| Jan 8, 2026 | Ebru Davidson director | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jul 8, 2026 |
| Jan 8, 2026 | John E. Friend II Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Jul 8, 2026 |
| Jan 8, 2026 | John E. Friend II Chief Executive Officer | AGrant or award Restricted Share Unitsderivative | -150,000 | $0.00 | $0 | 150,000 | Jul 8, 2026 |
| Jun 19, 2026 | Sudha Rao Chief Scientific Officer | AGrant or award Employee Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jun 23, 2026 |
| Jun 19, 2026 | James E. Levine Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jun 23, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Robert F Appledirector
- Jeffrey BonacordaVP, Finance and Controller
- David CainDirector, CMC
- Steven R. S. Coffeydirector
- Ebru Davidsondirector
- John E. Friend IIChief Executive Officer
- James E. LevineChief Financial Officer
- Sudha RaoChief Scientific Officer
Questions about KZIA
Answered from the filings on this page, as of the latest one.
Are insiders buying KZIA?
No. In the last 90 days no insider at KAZIA THERAPEUTICS LTD bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade KZIA on the open market?
No open-market trade has been scored at KAZIA THERAPEUTICS LTD. The latest Form 4 on file was filed on Jul 8, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at KAZIA THERAPEUTICS LTD?
8 people have filed a Form 4 at KAZIA THERAPEUTICS LTD, among them Robert F Apple (director), Jeffrey Bonacorda (VP, Finance and Controller), David Cain (Director, CMC). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.